MEDTECH & BIOPHARMA DEVICE CMO/CDMO MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

The global MedTech & biopharma device CMO/CDMO market is estimated to be valued at USD 110,227.2 Mn in 2026 and is expected to reach USD 271,758.5 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 13.8% from 2026 to 2033. The global MedTech & biopharma device CMO/CDMO market includes contract development and manufacturing services for medical devices, diagnostics, drug-device combination products, and drug delivery devices with high growth and innovation, as well as contract development and manufacturing services for devices and medical and healthcare applications. By functioning as outsourcing partners, CMOs/CDMOs help client companies design, engineer, provide and integrate regulatory, manufacturing, packaging and logistics.

The need to control operational and product development expenses, speed product to market, gain market access for new innovative products and leverage specialized know how is encouraging pharmaceutical, medical device, and biopharmaceutical industries to seek an outsourced product design, development and manufacturing partner solution. Increased usage of autoinjector devices and biologics delivery devices, wearable medicals devices, and associated healthcare devices will require partnerships with strategically positioned CMOs/CDMOs throughout the life science industry, including drug development and delivery device and drug device combinations.

Market Dynamics

The global MedTech & biopharma device CMO/CDMO market is driven by the rising level of outsourcing of device development and manufacturing functions. Adoption of drug device combination products, biologics delivery devices and connected devices for medtech devices is promoting life sciences players to attain CMO/CDMO competency to optimize time-to-market, manufacturing and cost efficiency.

However, a number of constraints are present in the market, such as stringent regulatory barriers, tedious validation process, and high-quality protection cost. These market limitations coupled with the bottlenecks in the supply chain and the limited capacity for niche manufacturing services pose hurdles to the market advancement. Nevertheless, increasing adoption of innovative drug delivery devices and wearable healthcare technologies as well as shift toward strategic outsourcing by emerging life sciences organizations will offer new opportunities for growth in MedTech & biopharma device CMO/CDMO market.

Key Features of the Study

• This report provides in-depth analysis of the global MedTech & biopharma device CMO/CDMO market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global MedTech & biopharma device CMO/CDMO market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Integer Holdings Corporation, Jabil Inc., Flex Ltd., Sanmina Corporation, Phillips-Medisize, Nordson MEDICAL, West Pharmaceutical Services, Gerresheimer AG, SteriPack Group, and Nipro Corporation
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global MedTech & biopharma device CMO/CDMO market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global MedTech & biopharma device CMO/CDMO market

Market Segmentation

• Product/Device Type Insights (Revenue, USD Mn, 2021 - 2033)
  • Drug-Device Combination Products
  • Medical Devices
  • Diagnostics and Laboratory Devices/Equipment
  • Other Product / Device Types
• Service Type Insights (Revenue, USD Mn, 2021 - 2033)
  • Design Development and Engineering Services
  • Contract manufacturing
  • Supply Chain Management
  • Quality and Regulations
  • Other Value-Added Services
• Device Class Insights (Revenue, USD Mn, 2021 - 2033)
  • Class I
  • Class II
  • Class III
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Integer Holdings Corporation
  • Jabil Inc.
  • Flex Ltd.
  • Sanmina Corporation
  • Phillips-Medisize
  • Nordson MEDICAL
  • West Pharmaceutical Services
  • Gerresheimer AG
  • SteriPack Group
  • Nipro Corporation